innovative platform technology

Innovative Technology Platform

Entera's innovative technology enables oral drug delivery of large molecules

27163516 pills

Pipeline of Drug Development

Entera conducts clinical trials of three oral drugs based on a proven active compound

27163516 brain green

Experienced Management Team

The managers of Entera have more than 50 years of experience in drug development

Hypoparathyroidism affects less than 5 in 10,000 people in the European Union (EU) or approximately 257,000 individuals. In the United States (US) The prevalence of hypoparathyroidism is estimated to be 37 per 100,000, with 78% of cases caused by surgery, 7% due to genetic disorder and 6% due to idiopathic origin. Although incidence rates have been difficult to quantify, it is estimated that chronic hypoparathyroidism, which affects patients for more than six months, affects approximately 58,700 insured individuals in the United States, with an estimated 43% of these chronic cases characterized as mild, 39% characterized as moderate, and 18% characterized as severe.